Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Abstract

BACKGROUND: The TOMAHAWK trial compared immediate coronary angiography with a delayed/selective strategy in 554 resuscitated patients with out-of-hospital cardiac arrest (OHCA) without ST-segment elevations. Mortality did not differ significantly between the two groups. In addition to survival, health-related quality of life (HRQoL) is a key outcome parameter for OHCA patients.

METHODS: The analysis included 169 survivors from the TOMAHAWK trial who completed both the 6-month and 12-month follow-up (6M-FU/12M-FU). HRQoL was assessed using a questionnaire based on the EuroQoL-5D-3L. This tool includes a visual analogue scale (EQ-VAS) ranging from 0 to 100 (worst to best imaginable subjective health) and a descriptive system with five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

RESULTS: No relevant differences were found between patients in the immediate angiography group and those in the delayed/selective angiography group regarding EQ-VAS scores at 6M-FU (70 ± 21 vs. 74 ± 18) and 12M-FU (72 ± 19 vs. 74 ± 17). Patients reported the most problems with usual activities (33% and 38%, respectively), and the fewest limitations in self-care (18% and 17%, respectively) at 6M-FU. Women reported more problems than men in all five dimensions. Elderly patients (≥65 years) were more likely than younger OHCA survivors to indicate limitations in mobility, self-care, usual activities, and pain/discomfort.

CONCLUSIONS: OHCA survivors of the TOMAHAWK trial rated their HRQoL 6 and 12 months after the event as relatively good, but there were notable differences between women and men and between younger and elderly patients. The angiography strategy did not affect HRQoL. www.ClinicalTrials.gov : NCT02750462.

OriginalspracheEnglisch
ZeitschriftEuropean heart journal. Acute cardiovascular care
Jahrgang14
Ausgabenummer9
Seiten (von - bis)511-519
Seitenumfang9
ISSN2048-8726
DOIs
PublikationsstatusVeröffentlicht - 01.09.2025

Fördermittel

The trial was fully supported by the German Center for Cardiovascular Research (DZHK) and carried out using the clinical-scientific infrastructure of the DZHK. The trial was fully supported by the German Center for CardiovascularResearch (DZHK) and carried out using the clinical-scientific infrastructure of the DZHK. Conflict of interest: C.H.: Research Grant from the Danish Heart Foundation. S.d.W.: Speaker honoraria from AstraZeneca, Boehringer Ingelheim, Edwards Lifesciences, and TherOx/Zoll; consultant to Pfizer-BMS and TherOx/Zoll Medical. Other authors: None.

TrägerTrägernummer
Deutsches Zentrum für Herz-Kreislaufforschung
German Center for CardiovascularResearch
Hjerteforeningen

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Quality of Life after Out-of-hospital Cardiac Arrest - A TOMAHAWK Substudy“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Zitieren